Professional Documents
Culture Documents
C A L I F O R N I A
D E N TA L
February 2016
Intraoral Lesions
Oropharyngeal Cancer
Oral Cancer Chemoprevention
A S S O C I AT I O N
ORAL CANCER:
NOVEL CONCEPTS
FOR THE ORAL
HEALTH CARE
PRACTITIONER
Diana V. Messadi,
DDS, MMSc, DMSc
Feb. 2016
C D A J O U R N A L , V O L 4 4 , N 2
D E PA R T M E N T S
75
139 Periscope
142 Tech Trends
F E AT U R E S
82 Oral Cancer: Novel Concepts for the Oral Health Care Practitioner
An introduction to the issue.
Diana V. Messadi, DDS, MMSc, DMSc
85 Managing Intraoral Lesions in Oral Cancer Patients in a General Dental Practice: An Overview
Patients with active cancer or a history of cancer may present with multiple side effects that dental practitioners
can manage or prevent. The authors discuss some of these concerns and provide management strategies.
Reuben Han-Kyu Kim, DDS, PhD; Paul Yang, BS, MS; and Eric C. Sung, DDS
F E B R U A R Y 2 0 1 6 71
C D A J O U R N A L , V O L 4 4 , N 2
CDA Classieds.
Free postings.
Priceless results.
Journa
C A L I F O R N I A
published by the
California
Dental Association
1201 K St., 14th Floor
Sacramento, CA 95814
800.232.7645
cda.org
CDA Ocers
Kenneth G. Wallis, DDS
PRESIDENT
president@cda.org
D E N TA L
A S S O C I AT I O N
Editorial
Upcoming Topics
March/Integrated Health
Systems
www.editorialmanager.
com/jcaldentassoc
EDITOR-IN-CHIEF
Kerry.Carney@cda.org
Ruchi K. Sahota, DDS, CDE
April/Changing Landscape
of Practice
ASSOCIATE EDITOR
May/Student Research
Advertising
ASSOCIATE EDITOR
Doug Brown
ADVERTISING SALES
Doug.Brown@cda.org
916.554.7312
GUEST EDITOR
Andrea LaMattina
presidentelect@cda.org
PUBLICATIONS SPECIALIST
Blake Ellington
VICE PRESIDENT
Permission and
Reprints
Andrea LaMattina
vicepresident@cda.org
COMMUNICATIONS
SECRETARY
SPECIALIST
PUBLICATIONS SPECIALIST
Andrea.LaMattina@cda.org
916.554.5950
Courtney Grant
Subscriptions
Subscriptions are available
only to active members of
the Association. The
subscription rate is $18 and
is included in membership
dues. Nonmembers can
view the publication online
at cda.org/journal.
Manage your subscription
online: go to cda.org, log in
and update any changes to
your mailing information.
Email questions or other
changes to membership@
cda.org.
Manuscript
Submissions
www.editorialmanager.
com/jcaldentassoc
TREASURER
treasurer@cda.org
Production
speaker@cda.org
Val B. Mina
Randi Taylor
pastpresident@cda.org
Go Digital cda.org/apps
Management
Peter A. DuBois
EXECUTIVE DIRECTOR
Jennifer George
CHIEF MARKETING OFFICER
Cathy Mudge
VICE PRESIDENT
PUBLIC AFFAIRS
Alicia Malaby
yourself at cda.org/classieds.
COMMUNICATIONS
DIRECTOR
Journal of the California Dental Association (ISSN 10432256) is published monthly by the
California Dental Association, 1201 K St., 14th Floor, Sacramento, CA 95814, 916.554.5950.
Periodicals postage paid at Sacramento, Calif. Postmaster: Send address changes to Journal
of the California Dental Association, P.O. Box 13749, Sacramento, CA 95853.
The California Dental Association holds the copyright for all articles and artwork published
herein. The Journal of the California Dental Association is published under the supervision of
CDAs editorial sta. Neither the editorial sta, the editor, nor the association are responsible for
any expression of opinion or statement of fact, all of which are published solely on the authority
of the author whose name is indicated. The association reserves the right to illustrate, reduce,
revise or reject any manuscript submitted. Articles are considered for publication on condition
that they are contributed solely to the Journal.
Copyright 2016 by the California Dental Association. All rights reserved.
72F E B R U A R Y 2 01 6
Assoc.
Editor
Editor
C D A J O U R N A L , V O L 4 4 , N 2
Renew today.
cda.org/member
Impressions
C D A J O U R N A L , V O L 4 4 , N 2
The nub:
1. Social fatigue is damaging
our willingness to help others.
2. Help is more likely to come
from one who shares your
problems than from experts.
3. No one cares how much you
know until he or she knows how
much you care.
F E B . 2 0 16
IMPRESSIONS
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
How Teeth Find Their Way to the Right Spot in the Jaw
Led by scientists at the University of
California, San Francisco, researchers
recently showed in mice that molar
progenitor cells migrate to their final
locations during development, rather
than forming the teeth in place, as
researchers had previously thought.
According to a news release from the
university, this is the first time researchers
have captured on video how teeth find
their way to the right spot in the jaw.
F E B . 2 0 16
IMPRESSIONS
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
Multiplying Teeth
Working with colleagues from the Tokyo Medical and Dental University,
researchers have found a way to, literally, multiply teeth. In mice, the researchers
were able to extract teeth germs the groups of cells formed early in life that later
develop into teeth split them into two and then implant the teeth into the mices
jaws where they developed into two fully functional teeth, according to a new
study in Scientic Reports, an online journal of the publishers of Nature.
To manipulate the teeth development process, the researchers removed
teeth germs from mice and grew them in culture. At an appropriate point in
the development process, which according to the authors turned out to be
14.5 days, they nearly sliced the germs in two with nylon thread, leaving
just a small portion attached, and continued to culture them. The hope was
that signaling centers, which control the wave of molecules that regulate the
development of the tooth, would arise in each part and this, in fact, was the
case. The ligated germs developed naturally into two teeth, which the team
transplanted into holes drilled into the jaws of the mice.
Though they were only half the size of normal teeth, the split teeth erupted
into the oral cavity and restored physiological tooth functions, including
mastication, periodontal ligament function and responsiveness to noxious
stimuli. Signicantly, the researchers also report that they were able to
manipulate the teeth using orthodontic methods, equivalent to braces, and the
bone properly remodeled to accommodate the movement of the teeth.
For details on this research, see the
Dec. 17, 2015, edition of Scientic Reports.
Photo of a tooth germ with a nylon noose (left)
and the noose tightened (right).
introduction
C D A J O U R N A L , V O L 4 4 , N 2
GUEST EDITOR
Diana V. Messadi,
DDS, MMSc, DMSc,
is a professor and chair
of the section of oral
medicine and orofacial
pain and the associate
dean for education and
faculty development at the
University of California,
Los Angeles, School of
Dentistry.
Conict of Interest
Disclosure: None reported.
introduction
C D A J O U R N A L , V O L 4 4 , N 2
84F E B R U A R Y 2 01 6
intraoral lesions
C D A J O U R N A L , V O L 4 4 , N 2
dental practitioners will encounter patients with active cancer or a history of cancer.
Typically, these patients may have had or are undergoing therapies such as surgery,
radiation, chemotherapy or a combination of therapies. These patients may present
with multiple side effects that dental practitioners can manage or prevent. We
discuss some of these concerns and provide management strategies.
AUTHORS
Reuben Han-Kyu Kim,
DDS, PhD, is an associate
professor, vice chair in the
section of restorative dentistry
and the course chair for
direct restorations for
predoctoral students at the
University of California, Los
Angeles, School of Dentistry.
He is actively engaged in
research related to oral
diseases including wound
healing and oral cancers.
Conict of Interest
Disclosure: None reported.
Paul Yang, BS, MS, is a
rst-year student in the DDS/
PhD combined program at
the University of California,
Los Angeles, School of
Dentistry. Mr. Yang earned
his bachelors and masters
degrees in biology from
UCLA. He is interested in
intraoral lesions
C D A J O U R N A L , V O L 4 4 , N 2
Chemotherapy
Oral Mucositis
Surgical Therapy
Surgical therapy for cancer is a
treatment choice, as it allows for the
physical removal of the entire tumor
mass. Following surgical removal, patients
may undergo adjuvant radiation or
chemotherapy for complete eradication of
86F E B R U A R Y 2 01 6
Radiation Therapy
C D A J O U R N A L , V O L 4 4 , N 2
Xerostomia
FIGURE 2A . Xerostomia causing gross decay
(arrows).
gumline (arrow).
intraoral lesions
C D A J O U R N A L , V O L 4 4 , N 2
mandibular dentition.
Osteoradionecrosis (ORN)
General description: Osteoradionecrosis
(ORN), as the name implies, means bone
death because of radiation. The incidence
of ORN ranges from 8 percent to 35 percent,
largely depending on observational periods
that range from months to years.14,15 Most
of ORN (about 75 percent) occurs within
the first three years of radiation therapy
treatment.16 ORN is more prevalent in the
mandible than the maxilla, owning to the
poor vascularization and increased density
that allows for absorbing more radiation
in the mandible. The cause of ORN is
still unclear although there are several
hypotheses, such as bacterial infection,
hypoxia and fibroatrophy.17-19 Risk factors
include location of primary tumor, cancer
staging, dose of radiation (> 60 Gy), poor
oral hygiene, alcohol and tobacco use and
invasive dental procedures such as tooth
extraction.20 It is noteworthy that, once
radiation therapy is delivered, cancer patients
have the risk of developing ORN that is
lifelong and does not decrease over time.
Therefore, thorough examination at each
visit for periodic examination is essential.
Clinical manifestation: ORN is clinically
defined as an area of exposed bone that
persists for more than three months
(FIGURE 4 ). However, radiographic
findings of irregular radio-opacity that is
indicative of sequestrum formation without
breached overlaying mucosal closure is
also common (FIGURE 5 ). Ulcerative
or necrotic soft tissues can also be seen
frequently around the exposed area.
Long-term exposure without proper oral
C D A J O U R N A L , V O L 4 4 , N 2
Trismus
Oral Candidiasis
General description: Oral candidiasis is
fungal lesions predominantly mediated by
the yeast Candida albicans. C. albicans occurs
naturally in the body including the oral
cavity. In a normal setting, it does not give
rise to any lesions, but candidiasis occurs
when there is a drastic change within the
oral environment (e.g., immunosuppression)
that favors its reproduction. As such, it is
often called an opportunistic infection.
Brown, et al. reported that irradiation
caused up to a hundredfold increases in
fungal populations.29 This increase in
fungal populations has significant clinical
implications and is often overlooked. During
the administration of radiation therapy,
acute candidiasis is likely to occur due to
altered immunity and xerostomia secondary
to hyposalivary functions in the oral cavity.30
intraoral lesions
C D A J O U R N A L , V O L 4 4 , N 2
FIGURE 9. MRONJ
MRONJ
General description: The first formal
report on osteonecrosis of the jaw (ONJ)
by bisphosphonates was published in
2003,34 but the etiology is still unknown.
Multiple hypotheses have been suggested,
including suppression of bone remodeling,
inflammation, inhibition of angiogenesis
and soft tissue toxicity.35 The terminology
of bisphosphonate-related osteonecrosis
of the jaw, or simply BRONJ, was recently
updated to MRONJ in order to be more
inclusive of medications other than
bisphosphonates, such as denosumab or
bevacizumab.36 MRONJ is clinically defined
as patients with a history of treatment with
antiresportive or anti-angiogenic agents,
exposed bone for more than eight weeks
and no history of radiation therapy to
the head and neck regions.36 A detailed
classification of MRONJ can be found
elsewhere.36 Individuals with advancedstage cancers that invade bone may take
these medications, usually intravenously or
C D A J O U R N A L , V O L 4 4 , N 2
TABLE
Types of
cancer therapy
Common
sites in the
oral cavity
Patients
chief
complaints
Clinical
manifestation
Goals of
management
Management
Oral mucositis
Radio/chemo
All
Pain
Erythematous
Ulcerative
To alleviate pain
Xerostomia
Radio/chemo
All
Thick or
ropey saliva
Rampant caries,
decalcication
To increase salivary ow
or substitutes
To prevent secondary
pathological events
(e.g., rampant caries,
infections)
Saliva substitutes
(carboxymethylcellulose, mucin,
water, glycin)
Salivary stimulants (pilocarpine,
cevimeline)
Osteoradionecrosis
Radio
Mandible
Nonhealing
and/or pain at the
exposed bony sites
Unpleasant mouth
smell
Exposed
bone, plaque
accumulation
Analgesics
Antibiotics
Antimicrobial rinse (0.12%
chlorhexidine)
Avoid invasive dental procedures
HBO chamber
Pentoxifylline/tocopherol
Trismus
Surgical/radio/
chemo
Mastication
muscles
Cannot open
mouth
Limited mouth
opening
Oral candidiasis
Radio/chemo
All
Burning sensation
White patches
that can rub o
To eradicate candidiasis
lesions
Altered taste
Radio/chemo
All
Cannot taste
None
None
MRONJ
Chemo
(for advanced
cancer)
Maxilla/
mandible
Nonhealing
and/or pain at the
exposed bony sites
Unpleasant mouth
smell
Exposed
bone, plaque
accumulation
Analgesics
Antimicrobial rinse (0.12%
chlorhexidine)
Good oral hygiene
Avoid invasive dental procedures
Conclusion
Once established, the relationship
between dentists and patients can last for
many years. As life expectancy increases
and advancement of medical technology
continues to grow, these relations may
potentially be lifelong. During that time,
F E B R U A R Y 2 0 1 6 91
intraoral lesions
C D A J O U R N A L , V O L 4 4 , N 2
92F E B R U A R Y 2 01 6
oropharyngeal cancer
C D A J O U R N A L , V O L 4 4 , N 2
dramatically changed over the past 30 years. It is now clear that human
papillomavirus (HPV) plays a major role in the incidence of head and neck cancers
in the general population and among patients with HIV infection. This article
reviews the current knowledge about oropharyngeal cancers for their epidemiology,
pathogenesis, clinical behavior, treatment and prevention. This review further
examines the subset of oropharyngeal cancers among the HIV-seropositive patients.
AUTHOR
Fariba S. Younai, DDS, is
a professor of clinical
dentistry in the section of
oral medicine and
orofacial pain in the
division of oral biology and
medicine at the University
of California, Los Angeles,
School of Dentistry, where
she currently serves as the
vice chair of the division of
oral biology and medicine.
Dr. Younai earned her
dental degree from the
School of Dental Medicine
at the State University of
New York at Stony Brook
and completed her training
in hospital dentistry at Long
Island Jewish Medical
Center in New York.
Conict of Interest
Disclosure: None reported.
oropharyngeal cancer
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
4
3.5
3
2.5
2
1.5
1
Oropharynx (overall)
HPV-negative oropharynx
HPV-positive oropharynx
.5
0
19881990
19911992
19951996
19992000
20032004
Surveillance Period
FIGURE 1. Incidence rates for overall HPV-positive and HPV-negative OPC (SEER data from Hawaii, Iowa and
oropharyngeal cancer
C D A J O U R N A L , V O L 4 4 , N 2
TABLE
TNM
Denitions
TX
T0
Tis
Carcinoma in situ
T1
T2
T3
Tumor invades the larynx, deep/extrinsic muscle of tongue, medial pterygoid, hard
palate or mandible
T4b
Nx
N0
N1
N2
Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6
cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6
cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more
than 6 cm in greatest dimension
N2a
Metastasis in a single ipsilateral lymph node more than 3 cm but not more than 6
cm in greatest dimension
N2b
N2c
N3
Mx
M0
No distant metastasis
M1
Distant metastasis
C D A J O U R N A L , V O L 4 4 , N 2
patient.
Clinical Considerations
As previously described, the great
majority of oropharyngeal cancers are
squamous cell carcinomas that are found,
for the most part, in the tonsillar complex
as well as the base of the tongue, the
soft palate and the posterior pharyngeal
wall. In clinical dental practice, a careful
visual assessment of the oral/pharyngeal
structures and the regional lymph nodes
with digital palpation is critical to
detecting cancerous lesions. In addition,
alarm symptoms such as trismus, dysphagia,
changes in tongue mobility and otalgia
should be further investigated for lesions
that may have penetrated deeper tissues in
Molecular Studies
As mentioned earlier, HPV-associated
OPSCC has better clinical prognosis, both
in terms of progression rate and response
to treatment. Although the exact reasons
for this phenomenon remain elusive,
among the proposed mechanisms are the
F E B R U A R Y 2 0 1 6 97
oropharyngeal cancer
C D A J O U R N A L , V O L 4 4 , N 2
Prevention Strategies
With an estimated life-long risk
of cervical HPV infection up to
80 percent among sexually active
women, HPV is considered the most
C D A J O U R N A L , V O L 4 4 , N 2
Conclusion
HPV-related oropharyngeal
cancers are increasing, and while HPV
vaccination can reduce the incidence
of these cancers, early clinical detection
and lower cancer staging is key to
patient survival after diagnosis. Focused
scientific research has started to produce
reliable prognostic molecular markers
and novel treatment approaches that,
once clinically validated and adopted in
everyday practice, can forever transform
the landscape of oropharyngeal cancer
detection, staging and treatment.
REFERENCES
oropharyngeal cancer
C D A J O U R N A L , V O L 4 4 , N 2
100F E B R U A R Y 2 01 6
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
Oral Cancer
Chemoprevention: Current
Status and Future Direction
Diana V. Messadi, DDS, MMSc, DMSc, and Kazumichi Sato, DDS, PhD
AUTHORS
Diana V. Messadi, DDS,
MMSc, DMSc, is a
professor and chair of the
section of oral medicine
and orofacial pain and the
associate dean for
education and faculty
development at the
University of California, Los
Angeles, School of
Dentistry.
Conict of Interest
Disclosure: None reported.
ancer chemoprevention
is defined as the use
of natural, synthetic
or biological chemical
agents to suppress,
reduce or prevent the progression of
carcinogenesis. The term was first
coined by Sporn et al.1 It is defined as
drugs that have an effect of slowing
or stopping cancer development and
preventing malignant transformation
of premalignant lesions. Clinicians
have considered that the best
target populations for oral cancer
chemoprevention are patients with
oral premalignant lesions (OPLs) and/
or postoperative oral cancer patients
without tumor bearing for prevention
of secondary primary tumors.2-4
One of the major obstacles in
chemoprevention studies to date has
been the inability to identify oral
lesions with a high risk of malignant
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
Green Tea
Similar to retinoids and betacarotene, green tea has been studied as a
chemopreventive agent for an extensive
period. The background for its use stems
from the idea that drinking green tea
reduces cancer risk.28 In Japan, with its
large population of tobacco users (around
20 percent of adults) and drinking green
tea as part of its culture, reports show that
oral cancer patients are about 1 percent
of all cancer patients and the prevalence
of OPL is 2.5 percent, which is lower than
other countries.25,30 The leading compound
in the mechanism of green tea cancer
chemoprevention is a type of polyphenol,
specifically, epigallocatechin-3-gallate
(EGCG). Studies showed that multiple
signal pathways are involved in the
inhibitory effect of polyphenols on cancer
cell growth.29-32 A phase II study reported
by Tsao et al. used three green tea dosages
including a 1,000 mg/m2 of green tea
extract based on a previous phase I study.20
The clinical response in this phase II study
did not reach statistical significance in
all green tea extract arms versus placebo.
However, the two higher-dose green tea
extract arms had higher responses (clinical
response), confirming dose-response effect
(TA BLE 1 ). Although some side effects
were observed, the therapy was well
tolerated and safe. They concluded that
these promising results supported longer-
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
TABLE 1
Summary of the Nine Studies (eligible participants, study design, control, location of study, sample size, registration period) 1524
Summary of the study
Author
Year
Agents
Eligible participants
Study design
(RCT: randomized
control trial)
Control
Location
Jyothirmayi
1996
Vitamin A
RCT
two-arm
Placebo
India
Khuri
2006
Isotretinoin
(13-cis retinoic acid)
Placebo
USA
Papadimitrakopoulou
2009
Isotretinoin
(13-cis retinoic acid)
Premalignant lesions
two-arm (open-label
trial) single-center
Beta-carotene + retinyl
palmitate
or retinyl palmitate
alone
USA
Nagao
2014
Beta-carotene
Leukoplakia
(never smoked or ex-smokers)
RCT
two-arm
multicenter
Placebo (50mg/day
vitamin c)
Japan
Tsao
2009
Premalignant lesions
Placebo
USA
Papadimitrakopoulou
2008
Cyclooxygenase-2
(COX-2)
Premalignant lesions
Placebo
USA
Armstrong
2013
Bowman-Birk inhibitor
concentrate
Leukoplakia, erythroplakia
USA
Mallery
2014
Freeze-dried black
raspberry
(black raspberry: BRB)
Premalignant lesions
(no tobacco use)
RCT
two-arm
multicenter
Placebo
USA
Sun
2010
ZengShengPing
(a mixture of
medicinal herbs)
Leukoplakia
RCT
two-arm
single-center
Placebo
China
C D A J O U R N A L , V O L 4 4 , N 2
Sample size
Registration
period
(enrolled period)
1992
19911999
1992 2001
no mention
39 patients completed
[agents 28, control 11]
(41: randomized patients)
20022008
50 patients completed
[agents 32, control 18]
(56: randomized patients)
20002004
89 patients completed
[agents 43, control 46]
(132: randomized patients)
19992009
40 patients
[agents 22, control 18]
no mention
19982001
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
TABLE 2
Administration Method (period, route of administration); Effects (evaluation point, endpoints, results of endpoints) in Nine Studies 1524
Administration method
Eects
Author
Year
Period
Route of administration
Evaluation point
Endpoints
Jyothirmayi
1996
1 year
Oral administration
200,000 IU/week
3 years
Khuri
2006
3 years
Oral administration
30mg/day (3x daily)
7 years
Papadimitrakopoulou
2009
3 years
Oral administration
0.5mg/kg/day (1 year)
0.25mg/kg/day (2 years)
5 years
Nagao
2014
1 year
Oral administration
10mg/day with 500mg/day
vitamin C
5 years
Tsao
2009
12 weeks
Oral administration
500mg/m2, 750mg/m2,
1000mg/m2
(3x daily)
12 weeks
Papadimitrakopoulou
2008
12 weeks
Oral administration
100mg or 200mg
12 weeks
Armstrong
2013
6 months
(PR,CR ) add 12
months
Oral administration
(powder + water)
600 C.I. units of BBIC/day
(2x daily)
6 months
Mallery
2014
3 months
Application
(4x daily)
3 months
Sun
2010
812 months
3 months
(after cessation of
treatment)
vit A: Vitamin A; N.S: not statistically signicant; GTE: Green tea extract; EGCG: epigallocatechin 3-gallate; PR: partial response; CR: complete response;
BBIC: Bowman-Birk inhibitor concentrate; LOH: loss of heterozygosity; BRB: black raspberry
106F E B R U A R Y 2 01 6
C D A J O U R N A L , V O L 4 4 , N 2
Results of endpoints
#0 vit A 11/56, placebo 5/50
#1 vit A 0/56, placebo 2/50
#0 N.S (Isotretinoin 130/590, placebo 131/600)
#1 N.S (Isotretinoin 84/590, placebo 98/600)
#2 N.S (recurrence-free survival P=0.21)
#3 N.S (P=0.15)
#4 N.S (P=0.73)
#0 N.S (P=0.29)
#1 refer to Table 2 side eects and adverse eects section
#2 N.S
#3 N.S
#0 N.S (P=0.346: 1 year observation period)
#1 Cases of malignant transformation: experimental
2/23, placebo 3/23
(60 months of the median duration of follow-up)
#0 Clinical response: versus placebo (P=0.09),
histological response: versus placebo (P=0.65)
#1 The incidence of insomnia and nervousness
was higher in patients receiving GTE at 750 and
1,000 mg/m2
#2 No mention of treatment side eects
#3 1,000 mg/m2 dosing was most likely the reason for
the increased insomnia and nervousness
#0 N.S (P=1.0)
#1 N.S (P=0.71)
#0 N.S (P>0.94)
#1 No mention
#2 N.S (n=88)
#3 N.S (n=45)
#4 N.S (n=45)
#5 N.S (n=41)
#0 BRB versus Control P<0.01
#1 BRB (pre versus post P<0.05), Control (pre versus
post P=0.496)
#2 BRB (pre versus post P<0.005), Control (pre versus
post P=0.160)
#3 BRB versus Control P<0.005
#0 P<0.01
#1 P<0.05
Discussion
Surrogate Endpoint and Biomarkers
The endpoint of any clinical trial
addressing oral cancer chemoprevention
in OPL is prevention of malignant
transformation. Among nine studies
summarized in TA B L E 2 , four studies
using retinoids set carcinogenesis as
the endpoint.16-19 However, when
duration and frequency of malignant
transformation are considered, surrogate
endpoints have to be set. The National
Institutes of Health (NIH) defines
surrogate endpoint as a biomarker
intended to substitute for a clinical
endpoint. Some studies establish
surrogate endpoint according to the
mechanisms of chemoprevention agents,
such as LOH, DNA hypermethylation
and NF-kB signaling.4 Martinez et al.60
emphasized the importance of LOH on
chromosomes 3p and 9p as a surrogate
biomarker and using it as one of the
inclusion criteria for eligible lesions
having a high possibility of malignant
transformation. A study by Mao et al.61
reported that seven out of 19 patients
with an OPL and LOH at 3p14 and/or
9p21 developed head and neck squamous
cell carcinoma (HNSCC) whereas one
of 18 patients with an OPL without LOH
at 3p14 and/or 9p21 developed HNSCC.
The EPOC study set eligible participants
as those who demonstrated LOH at
3p14 and/or 9p21; so one of the key
features of EPOC study is recognized to
confirm molecular risk assessment of oral
cancer.49 Studies for green tea, presented
in this review, examined the expression
of vascular endothelial growth factor
(VEGF), p53, Ki-67, Cyclin D1 and the
p16 promoter methylation as surrogate
endpoints using green tea extract as a
chemopreventive agent. They showed no
difference in biomarker expression in spite
of the presence of a clinical response.20,29-31
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
TABLE 3
Effects (side effects and adverse effects); Qualities of the Nine Studies 1524
Eects (results)
Qualities of study
Author
Year
Side eects
Adverse eects
Jyothirmayi
1996
Khuri
2006
Papadimitrakopoulou
2009
Nagao
2014
*Company participation.
(No mention of conict of interest.)
Tsao
2009
Papadimitrakopoulou
2008
Armstrong
2013
Mallery
2014
Sun
2010
13cRA: 13-cis retinoic acid; GTE: green tea extract; BRB: black raspberry
108F E B R U A R Y 2 01 6
Other bias
C D A J O U R N A L , V O L 4 4 , N 2
chemoprevention
C D A J O U R N A L , V O L 4 4 , N 2
ACKNOWLEDGMENT
C D A J O U R N A L , V O L 4 4 , N 2
F E B R U A R Y 2 0 1 6 111
stem cells
C D A J O U R N A L , V O L 4 4 , N 2
of cancer stem cells (CSCs), or the CSCs hypothesis, may help to explain the high
mortality, low response to treatment and tendency of developing multiple tumors in
oral cancer. We will review current knowledge of the CSCs hypothesis in oral cancer
and the traits displayed by CSCs, focusing on the resistance to therapy and attempts
being made to treat oral cancer by specifically targeting CSCs.
AUTHORS
Qilin Xu, MD, PhD, is a
clinician scientist who
studies stem cells and
cancer. She has extensive
expertise in tumor
microenvironment, cancer
metastasis and cancer stem
cells. Dr. Xu currently
directs independent
research projects in the oral
and maxillofacial surgery
research lab at the
University of Pennsylvania
School of Dentistry.
Conict of Interest
Disclosure: None reported.
112F E B R U A R Y 2 01 6
C D A J O U R N A L , V O L 4 4 , N 2
Normal cells
Cancer stem
cells (CSC)
Self-renewal
FIGURE 1B. The cancer stem cell model postulates that cancer is organized in
a hierarchical structure that, at least in part, resembles that of the tissue of origin.
The tumorigenic potential is limited to the cancer stem cell subpopulation and its
cellular heterogeneity is a product of multipotent cancer stem cells.
stem cells
C D A J O U R N A L , V O L 4 4 , N 2
Identication of CSCs
By definition, both CSCs and normal
tissue stem cells possess self-renewal capacity;
however, self-renewal is typically deregulated
in CSCs. For many cancers, CSCs represent
a distinct population that can be prospectively isolated from the remainder of the
tumor cells and can be shown to have
long-term clonal repopulation and selfrenewal capacity the defining features of a
CSC. CSCs are defined by their ability to:
Generate a xenograft that is
representative of the parent tumor.
Self-renew as demonstrated by
serial passages in a xenograft
assay at clonal cell doses.
Give rise to daughter cells that may
possess proliferative capacity but are
unable to establish or maintain the
tumor clone upon serial passages.23
C D A J O U R N A L , V O L 4 4 , N 2
stem cells
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
Tumor
degenerate
Tumorigenesis
CSC-targeted
therapy
Tumor regression
Elimination of CSCs
Heterogeneous
tumor cells
Conventional
cancer therapy
FIGURE 2. Therapeutic implications of cancer stem cells. Cancer stem cells (red) self-renew and dierentiate within the tumors to form additional cancer stem cells as well as transient
amplifying cells (green) and dierentiated tumor cells (blue), which have limited proliferative potential. Conventional therapy that kills primarily nontumorigenic cancer cells can shrink
tumor size, but is not able to eliminate cancer stem cells (CSCs), which are the potential players in recurring tumor and metastasis. Targeting CSCs can lead to tumor regression.
stem cells
C D A J O U R N A L , V O L 4 4 , N 2
C D A J O U R N A L , V O L 4 4 , N 2
of the tumor-microenvironment
interplay. Taking into account the
complex modalities of activation of these
pathways, the identification of predictive
biomarkers remains a challenge, ideally
requiring biomarker measurement within
a microenvironmental context. It is also
worth considering that the therapeutic
potential of self-renewal pathway
antagonists could be counterbalanced by
potential serious adverse events because
of interference with crucial mechanisms
of tissue homeostasis. Therefore, a
deeper understanding of adult stem
cell biology is required to determine a
therapeutic window for anti-CSC agents.
Conclusion
The cancer stem cells hypothesis
opens up a wide field for future research
and further validation is needed to obtain
better understanding. An important
aspect is the reliability of identifying and
characterizing CSCs based on the cell
surface markers. This would offer a more
precise knowledge of the type of cells that
generate a tumor, their tissue distribution,
the relationships with their progenies
and the implications of their proliferative
activity and invasive capacity for
the prognosis of cancer patients. A
greater understanding of the biological
properties of CSCs could also lead to
the development of novel antitumor
drugs that can specifically target these
cells. The optimal therapy should aim at
targeting not only those cells undergoing
differentiation (bulk tumor population)
but also those resistant CSCs and
concomitantly destroying the CSC niche
for the survival. Thus, it is hoped that
this novel strategy will result in a rapid
exclusion of all tumor cell subpopulations
and avoid the possible repopulation of
the tumor mass by tumor-initiating cells
or by originally differentiated tumor cells
that have regained renewal activity.
REFERENCES
stem cells
C D A J O U R N A L , V O L 4 4 , N 2
277(2):227-34.
26. Loebinger MR, et al. Squamous cell cancers contain a side
population of stem-like cells that are made chemosensitive by ABC
transporter blockade. Br J Cancer 2008 98(2):380-7.
27. Zhang Q. et al. A subpopulation of CD133(+) cancer stem-like
cells characterized in human oral squamous cell carcinoma confer
resistance to chemotherapy. Cancer Lett 2010 289(2):151-60.
28. Bianchini C, et al. Targeted therapy in head and neck cancer.
Tumori 2011 97(2):137-41.
29. Slaughter DP, Southwick HW, Smejkal W. Field cancerization
in oral stratied squamous epithelium; clinical implications of
multicentric origin. Cancer 1953 6(5):963-8.
30. Suresh A, et al. Resistance/response molecular signature
for oral tongue squamous cell carcinoma. Dis Markers 2012
32(1):51-64.
31. Gallmeier E, et al. Inhibition of ataxia telangiectasia- and Rad3related function abrogates the in vitro and in vivo tumorigenicity
of human colon cancer cells through depletion of the CD133(+)
tumor-initiating cell fraction. Stem Cells 2011 29(3):418-29.
32. Qiao B, et al. The expression prole of Oct4 and Sox2 in
the carcinogenesis of oral mucosa. Int J Clin Exp Pathol 2014
7(1):28-37.
33. Brabletz T, et al. Opinion: Migrating cancer stem cells an
integrated concept of malignant tumour progression. Nat Rev
Cancer 2005 5(9):744-9.
34. Song J, et al. Characterization of side populations in HNSCC:
Highly invasive, chemoresistant and abnormal Wnt signaling. PLoS
One 2010 5(7): e11456.
35. Thiery JP, et al. Epithelial-mesenchymal transitions in
development and disease. Cell 2009 139(5):871-90.
36. Wellner U, et al. The EMT-activator ZEB1 promotes
tumorigenicity by repressing stemness-inhibiting microRNAs. Nat
Cell Biol 2009 11(12):1487-95.
37. Chen YC, et al. Aldehyde dehydrogenase 1 is a putative marker
for cancer stem cells in head and neck squamous cancer. Biochem
Biophys Res Commun 2009 385(3):307-13.
38. Batlle E, et al. The transcription factor snail is a repressor of
E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol
2000 2(2):84-9.
39. Ota I, et al. Snail-induced EMT promotes cancer stem cell-like
properties in head and neck cancer cells. Oncol Rep 2015.
40. Yang MH, et al. Bmi1 is essential in Twist1-induced epithelialmesenchymal transition. Nat Cell Biol 2010 12(10):982-92.
41. Syrjanen S. The role of human papillomavirus infection in head
and neck cancers. Ann Oncol 2010 21 Suppl 7:vii243-5.
42. Chaturvedi AK, et al. Human papillomavirus and rising
oropharyngeal cancer incidence in the United States. J Clin Oncol
2011 29(32):4294-301.
43. Ang KK, et al. Human papillomavirus and survival of patients
with oropharyngeal cancer. N Engl J Med 2010 363(1):24-35.
44. Semrau R, et al. Prognostic impact of human papillomavirus
status, survivin and epidermal growth factor receptor expression
on survival in patients treated with radiochemotherapy for very
advanced nonresectable oropharyngeal cancer. Head Neck 2013
35(9):1339-44.
45. Fakhry C, et al. Improved survival of patients with human
papillomavirus-positive head and neck squamous cell carcinoma in
a prospective clinical trial. J Natl Cancer Inst 2008 100(4):261-9.
46. Evander M, et al. Identication of the alpha6 integrin as a
candidate receptor for papillomaviruses. J Virol 1997 71(3):244956.
47. Masand RP, et al. Adenosquamous carcinoma of the head
and neck: Relationship to human papillomavirus and review of the
120F E B R U A R Y 2 01 6
at anhle@dental.upenn.edu.
nanodiamonds
C D A J O U R N A L , V O L 4 4 , N 2
A Chemopreventive
Nanodiamond Platform
for Oral Cancer Treatment
Albert Yen, BS; Kangyi Zhang, PhD; Giulia Daneshgaran, BS; Ho-Joong Kim, PhD;
and Dean Ho, PhD
surgery with chemotherapy and/or radiotherapy. This treatment paradigm has not
changed in some time. In this paper, we propose a chemopreventive nanodiamond
platform for the delivery of celecoxib (Celebrex) to oral cancer lesions. This
innovative platform allows for sustained drug release under physiological conditions,
potentially enhancing chemopreventive efficacy of celecoxib without the physical
and toxicological damage associated with conventional means of drug delivery.
AUTHORS
Albert Yen, BS, is in the
department of
bioengineering, Henry
Samueli School of
Engineering and Applied
Science at the University of
California, Los Angeles.
Conict of Interest
Disclosure: None reported.
Kangyi Zhang, PhD, is in
the division of oral biology
and medicine at the
University of California, Los
Angeles, School of
Dentistry.
Conict of Interest
Disclosure: None reported.
Giulia Daneshgaran,
BS, is in the department of
integrative biology and
physiology at the University
of California, Los Angeles.
Conict of Interest
Disclosure: None reported.
pproximately 45,780
Americans were diagnosed
with oral cancer in 2015.1
Treating oral cancer usually
requires surgical resection
with postoperative chemotherapy and/
or radiotherapy.2,3 Although the fiveyear survival rate from 2004 to 2010
for oral cancer patients was 66 percent,
modern treatments for oral cancer
are not without obstacles.1 Surgery is
physically traumatic, and radiotherapy
often leads to adverse physiological
effects, including infection and oral
mucositis.3 Chemotherapy subjects
patients to drug toxicity, and the
effectiveness of chemotherapy is often
hampered by poor drug bioavailability,
drug resistance and limited cellular
uptake. Furthermore, close to onethird of oral cancer patients undergo
a disease relapse after treatment.2
nanodiamonds
C D A J O U R N A L , V O L 4 4 , N 2
wide variety of nanodiamond surface modications. These surface modications facilitate the adsorption
or chemical conjugation of a broad range of molecular therapeutics. (Reprinted with permission from
Nature Publishing Group, 2012.)
C D A J O U R N A L , V O L 4 4 , N 2
Polyethyleneimine
800
Poly(ethylene
glycol) Diacid 600
Neutral
charge
Positive
charge
Arginylglycylaspartic
acid
Celecoxib
FIGURE 3A .
FIGURES 3. Carboxylated nanodiamond (NDCOOH) (3A ) is functionalized with polyethyleneimine
250
200
150
100
50
0
Hydrodynamic size (nm)
-potential (mV)
-50
ND-COOH
ND-PEI
ND-PEI-PEG
ND-PEI-PEGRGD
ND-Cxb
(no RGD)
ND-Cxb
(with RGD)
FIGURE 3B .
generated from stock ND after heattreating at 475 degrees Celsius for three
hours and resuspended in deionized
water. Coupling reagents 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide
(EDC) and N-hydroxysuccinimide
(NHS) were used to facilitate a
series of two consecutive EDC/NHS
coupling reactions, performed in
water at pH 5.5-6.0: conjugation of
polyethyleneimine 800 (PEI) to carboxyl
groups on the surface of ND-COOH
and conjugation of poly(ethylene
glycol) diacid 600 (PEG) to terminal
amine groups on PEI. A water wash
was performed between each coupling
reaction to remove excess reagents.
nanodiamonds
C D A J O U R N A L , V O L 4 4 , N 2
50
45
40
35
30
25
20
15
10
5
0
0
pH5
pH1
200
400
600
800
1000
Time (minutes)
1200
1400
1600
FIGURE 5A .
Neutral charge
Positive charge
Celecoxib
FIGURE 5B .
FIGURES 5 . Cxb release from ND-Cxb complexes (no RGD) (5A ) is measured over a period of 24 hours (1,440
minutes) under pH 1 (red) and pH 5 (blue) conditions. A greater initial burst release is observed under pH 1 conditions,
but average Cxb concentrations gradually decrease to similar baseline levels (n = 4, error bars = standard deviation). The
high pKa of the amine groups on PEI (5B ) may lead to preferential celecoxib release from the ND-Cxb at low pH, possibly
triggering the proton sponge eect. Under acidic conditions like those found in the cell endosome, the amine groups
on PEI are protonated, dissociating the ND-Cxb complex due to electrostatic repulsion. The dissociation of the ND-Cxb
complex subsequently releases Cxb into the endosome. The PEI also acts as a proton sponge, removing protons from the
endosome and generating a negative proton gradient. This negative proton gradient could initiate an inux of protons (and
therefore intracellular medium) from the intracellular space, rupturing the endosome and releasing Cxb into the cell.
C D A J O U R N A L , V O L 4 4 , N 2
PBS
Dox 100 g
NDX 100 g
Dox 200 g
NDX 200 g
12
100
Survival probability (%)
9
6
3
0
9 12 15 18
40
20
6 12 18 24 30 36 42 48 54 60
Days after implantation
TUNEL
H&E (200x)
H&E
Treatment
Dox 100 g
Dox 200 g
NDX 100 g
NDX 200 g
PBS
60
80
delivery system was in a glioma mice model. Hematoxylin and eosin (H&E) stains (top
and middle row) of treated glioma tissue showed that NDX treatment led to signicant
tumor regression compared to doxorubicin, ND and PBS controls. The H&E stains were
validated with a TUNEL stain, which stains apoptotic cells green (bottom row). (Reprinted
with permission from Elsevier, 2014.)
nanodiamonds
C D A J O U R N A L , V O L 4 4 , N 2
Anti-EGFRNDLP-Epi
NDLP-Epi
Epi
PBS
Therapeutic Outlook
Preclinical studies conducted with
similar ND-based delivery systems have
already returned promising results. The first
of these preclinical studies involved the
treatment of highly chemoresistant mice
mammary tumors with ND-doxorubicin
conjugates (NDX).12 NDX was able
to overcome drug efflux transporters
commonly found in chemoresistant tumor
strains, ensuring drug retention, whereas
free drug would be effluxed out of the cell.12
Mice treated with NDX were also able
to tolerate a double dose of doxorubicin,
showing significantly improved tumor
regression compared to a free doxorubicin
control (FIGURE 6A ).12 In fact, when
delivered in its free form, this double dose
of doxorubicin killed the mice before the
end of the treatment period (FIGURE 6B ).
The efficacy of NDX was also
studied in a mice model of glioblastoma
multiforme, an aggressive brain cancer
with high mortality rates.32 NDX and
free doxorubicin were delivered directly
C D A J O U R N A L , V O L 4 4 , N 2
dean.ho@ucla.edu.
F E B R U A R Y 2 0 1 6 127
^
KZE'KhEdz
>K^E'>^KhEdz
KtEz'W^
^W<
<W/
hZdd<
WWK
W/
'>E>'W
yE,DK<D
ZW/
,hEd/E'dKEWZ<'W
^E<W/
>tE>d
,
,
>'
W
6 2/ '
E,K>>ztKK'W
WWK
WW
/
E,K>>ztKK
Z&
W
<W/
W^E>/
K
>W/
WKDKE>/
KD
W/
dKZZE'W
W
<E<W/
t^dKs/E>/
K
&
D'
W/
t^dKs/E'W
,
y^
<W/
^E/'KKhEdz
D/^^/KEs/:K>/
KD
,
Z
W/
D/^^/KEs/:K>/
K
>
'W/
EtWKZd,'W
WWKW<
<W/
KZE''W
K
E<W/
KZE'>/
KD
t
KW/
ZE,K^dDZ'Z/d^
W<Ed
<W/
6 2/ '
^EdEd'W
EK
,DKW<W/
<ZEsEdhZKhEdz^E>h/^K/^WK
<Z^&/>WZ'Wd
W<
W/
6 2/ '
^E>h/^K/^WKKhEdz
<W/
st^D
WWs
>EdZK'Wd
W<
<W/
K'W/
W
</
WKtz'W,
W</
6 2/ '
^E/'K'W
WD
Ed<W/
Z/sZ^/^EZEZ/EKKhEdz
WW>s>>z^
D<E<W
/
,/EK>/
d
W/
/E/Et>>^'WD
/
W/
6 2/ '
DhZZ/dt
WWK
hzZ^EdK&<W/
W>D^Zdt
d
/
EdK&<W/
W>D^WZ/E'^'
^^
hzZ^EdK&<W/
Z/sZ^/'W
,
W</
ttt>WZd/^>^KD
Z
RM Matters
C D A J O U R N A L , V O L 4 4 , N 2
It takes thoughtful
coordination between
the dentist and patients
physician prior to dental
treatment, especially when
it comes to medically
compromised patients.
You are also not a sales goal or a market segment. You are a dentist.
And we are The Dentists Insurance Company, TDIC. Its been 35 years
since a small group of dentists founded our company. And, while times
may have changed, our promises remain the same: to only protect
dentists, to protect them better than any other insurance company and to
be there when they need us. At TDIC, we look forward to delivering on
these promises as we innovate and grow.
Contact the Risk Management Advice Line at 800.733.0634.
F E B R U A R Y 2 0 1 6 129
F E B . 2 0 16
RM MAT TERS
C D A J O U R N A L , V O L 4 4 , N 2
Hire
Post jobs
Search
Personality tests
Value assessments
Skills
Work culture assessments
Tonya Lanthier, RDH
CEO, DentalPost.net
130F E B R U A R Y 2 01 6
1.
2.
3.
4.
5.
6.
LEE SKARIN
& ASSOCIATES INC.
Your calls are invited. Put our thirty years of experience to work for you!
Visit our website for current listings: www.LeeSkarinandAssociates.com
2IFHV
805.777.7707
818.991.6552
800.752.7461
F E B . 2 0 16
RM MAT TERS
C D A J O U R N A L , V O L 4 4 , N 2
Smart dentist
tist ip ops
that lett you leave an
impression
pression wherever
you go.
132F E B R U A R Y 2 01 6
Practices
Wanted
SOUTHERN CALIF
CALIFORNIA
NORTHERN
NORT
RN CALIFORNIA
(415) 899-8580 (800) 422-2818
Raymond and Edna Irving
Ray@PPSsellsDDS.com
www.PPSsellsDDS.com
Dr. Lee
Maddox
LIC #01801165
Dr. Thomas
Wagner
LIC #01418359
Dr. Dennis
Hoover
LIC #0123804
Dr. Russell
Okihara
LIC #01886221
Jim
Engel
LIC #01898522
Kerri
McCullough
LIC #01382259
Mario
Molina
LIC #01423762
Jaci
Hardison
LIC #01927713
Steve
Caudill
LIC #00411157
Thinh
Tran
LIC #01863784
(949) 675-5578
25 Years in Business
(916) 812-3255
40 Years in Business
(209) 605-9039
36 Years in Business
(619) 694-7077
33 Years in Business
(925) 330-2207
42 Years in Business
(949) 566-3056
35 Years in Business
(949) 675-5578
35 Years in Business
(949) 675-5578
26 Years in Business
(951) 314-5542
25 Years in Business
(949) 675-5578
11 Years in Business
PINOLE:2SV(QGRRIFHZ'LJLWDO;UD\
Microscopes, and PBS Endo in approx. 1,200
sq. ft. 2014 GR $672K. #CA284
ROSEVILLE/GRANITE BAY: 1,320
sq. ft., 3 equip. Ops, 1 addl Plumbed. Dexis
Digital X-ray. 2014 GR $434K. #CA296
SACRAMENTO: 1,684 sq. ft., 6 equip.
stations in bay, 2 addl Plumbed. 2014 GR
$590K. #CA269
SACRAMENTO: Russian-speaking. 4 Ops,
1,500 sq. ft.. All new Equipment, practice
started recently. $1M over last 12 months.
#CA290
SACRAMENTO: 2,500 sq. ft., 6 equip. Ops,
1 addl Plumbed. Dentrix software, Digital
X-ray, Pano. 2014 GR $788K. #CA297
SAN FRANCISCO: Periodontal Practice
& Condo Unit. 1,160 sq. ft. w/4 Ops, 2014
GR $714K w/$363K adj. net. #CA274
SAN RAMON: FACILITY ONLY, 1,654 sq.
ft., 4 Ops. Pelton & Crane Equipment, Digital
X-ray, Digital Pan, I.O. cameras. #CA306
SANTA ROSA: General Dentistry &
Building. 3 Ops. 2013 GR $542K w/Adj. Net
$182K. #CA200
SONOMA:6WDQGDORQHVTIWRIFH
w/4 Ops. Digital X-rays, Lasers, CAD/CAM.
2014 GR $675K on 3 day/week. #CA270
CENTRAL CALIFORNIA
N. OF SACRAMENTO:VTIWRIFH
w/4 Ops, Dentrix, Pano. Owner worked 39
weeks in 2014. #CA267
SOUTHERN CALIFORNIA
OLD
1.800.519.3458
OLD
S
WHITTIER: General Dentistry. 4 Ops,
SAN DIEGO
CHULA VISTA: Est. 50+ yrs. 4 Ops, 3
days of Hygiene, Dentrix. $493K GR in 2013.
#CA109
CHULA VISTA EAST: New Listing!
General Dentistry. 3 Ops. Est. 19 years.
Professional bldg. 2014 GR $454K. #CA304
COLLEGE AREA: Very busy 6 Ops with
room to expand to 9 Ops. PPO, Dentrix,
Digital. 2014 GR $1.7MM #CA231
DOWNTOWN: LEASEHOLD SALE.
0RGHUQDQGFKLFGRZQWRZQRIFHLQSULPH
location. 3 Ops + room to expand. #CA232
SOL
SOL
SOL
OUT OF CALIFORNIA
www.henryscheinppt.com
1.888.685.8100
16PT3352J
Regulatory Compliance
C D A J O U R N A L , V O L 4 4 , N 2
Linda Brown
30 Years of Experience Serving
the Dental Community Proven
Record of Performance
F E B R U A R Y 2 0 1 6 135
F E B . 2 016 R E G U L ATO RY C O M P L I A N C E
C D A J O U R N A L , V O L 4 4 , N 2
INVENTORY IS LOW!
ITS A SELLERS MARKET!
Paul Maimone
Broker/Owner
ARCADIA (4) op comput G.P. Located in a well known Prof. Bldg. on a main thoroughfare.
Cash/Ins/PPO pt base. Annual Gross Collect $300K+ on a (3) day week.
BAKERSFIELD #29 - (4) op comput G.P. (3) ops eqtd, (1) add. plumbed. Located in a free
stand bldg. Cash/Ins/PPO. Digital x-rays. Annual Gross Collect $300K+ p.t. Seller moving.
BAKERSFIELD #31 - Free Stand. Bldg. & Pract. (4) op comput G.P. w excell. exposure &
signage. (3) ops eqt./4th plumbed. Annual Gross Collect $325K+ Cash/Ins/PPO. NEW
CAMARILLO (3) op compt. G.P. 2 eqtd./3rd has a Pano. Cash/PPO. $120K Gross p.t. NEW
GROVER BEACH - (3) op Turnkey Office w included charts (included, but not guaranteed). (2)
ops eqtd w newer eqt. 3rd plmbed. Networked, digital Pano & x-ray. Dentrix. In a strip ctr. NEW
MONTEBELLO - (4) comput G.P. (2) ops eqtd. Located in a busy shop. ctr. w exposure &
visibility. Annual Gross Collect. $200K on a p.t. schedule. Cash/Ins/PPO. Seller retiring. NEW
MONTEREY PARK (6) op comput G.P. located in a street front suite on a main thoroughfare
w exposure/visibility. Cash/Ins/PPO/Small % Denti-Cal. Gross Collect $250K+ p.t. REDUCED
MURRIETA (5) op comput. G.P. (4) ops eqtd/(1) add. plumb. Cash/PPO patients. No HMO
or Denti-Cal. Located in a condo (also available), in a smaller prof. bldg.. Gross Collect approx..
$400K/yr. Seller is giving up private practice for a Govt. position. Motivated!
OXNARD (4) op comput. G.P. in a prof. bldg. Gross Collect ~ $250K/yr on (3) days. Digital xrays. Dentrix. Cash/Ins/PPO/HMO/Denti-Cal. Refers diff Endo/O.S./Perio & Ortho. NEW
SANTA BARBARA COUNTY (3) op comput G.P. & a 1,900 sq ft Bldg. that houses the
practice & a residential unit that can be rented or lived in. Fee for Service. No PPO, HMO or
Denti-Cal. 2015 Gross Collections ~ $275K on a relaxed 3 day week. Seller refers all O.S.,
Perio, Ortho, Endo & implant placement. Seller retiring but will assist w transition. NEW
SHERMAN OAKS (3) op comput G.P. in a well known Med/Dental bldg. Fee for Service.
Annual Gross Collect $160K+ p.t. Great Starter or Satellite. Seller retiring. REDUCED
So. KERN COUNTY (6) op comput. G.P. located in a Bakersfield suburb in a small strip ctr. w
exposure/visibility. Pano eqtd. Limited competition. Cash/Ins/PPO pts. Annual Gross Collect.
Approx. $350K p.t. Used to do $1M+ f.t.. Seller is moving and is motivated. REDUCED
SAN FERNANDO VALLEY - (8) op comput. G.P. w modern equipt. Located in a prof. bldg. on
a main thoroughfare. Cash/Ins/PPO/HMO. Cap Ck approx $7K/mos. Collect $1.3M+/yr. NEW
SANTA ANA - absentee owned (6) op fully eqtd G.P. First floor street front location on a main
thoroughfare. Exposure/visibility/signage. Cash/Ins/PPO. No HMO & No Denti-Cal. Pano eqtd
& Computerized. Annual Gross Collect. ~ $525K on a (3) to (4) day Associate run week.
TUSTIN - (4) op comput. G.P. (3) ops eqtd/4th plumbed. Located in a busy shop ctr. on a main
thoroughfare. Excellent exposure, visibility, signage & parking. Digital x-rays. Turnkey Office
w some pt. charts included but not guaranteed. SOLD
THOUSAND OAKS (4) ops/(2) eqtd comput. Turnkey Office with included charts. Chart
included but not guaranteed. Located in a condo in a Prof. Bldg. on a main thoroughfare. NEW
UPCOMING PRACTICES: Bakersfield, Beverly Hills, Central Coast, Covina, Downey,
Duarte, Goleta, Oxnard, Pomona, San Gabriel, Torrance, Van Nuys, Visalia & West L.A..
D&M SERVICES:
Q Practice Sales and Appraisals
Q Practice Search & Matching Services
Q Practice and Equipment Financing Q Locate and Negotiate Dental Lease Space
Q Expert Witness Court Testimony
Q Medical/Dental Bldg. Sales & Leasing
Q Pre - Death and Disability Planning Q Pre - Sale Planning
136F E B R U A R Y 2 01 6
CARROLL
& C O M P A N Y
Complete Evaluation of Dental Practices & All Aspects of Buying and Selling Transactions
www.carrollandco.info dental@carrollandco.info
4010 SF GP
State-of-the-art, modern dental practice in gorgeous facility with
recently upgraded reception, business and private office in
approx. 3,200 sq. ft. office
ce
e with
Gw 6 fully equipped ops. Located
IpNme
close to downtown.
wn.. Equipment
Equ
qD
uip
men
e includes Inter-oral camera, laser,
N
digital x-ray, air aabrasive,
Omnicam, Cerec, and implant system.
bPas
br
aEsiv
asi
iv Omn
ive,
2014 Gross Receipts
i t over $1.3
$1 Million. 2015 on schedule for
$1.6 Million. Asking $1.1 Million.
4086 SILICON VALLEY PERIO
Well-established Perio practice in prime San Jose location with
referral sources nearby. Located in a commercial & residential
mix neighborhood with a large daytime business draw. Approx.
1,100 sq. ft. office with 4 fully-equipped ops. Well trained
dedicated staff, seller retiring and willing to help for smooth
transition. 2014 GR $482K+, 2015 on schedule for $539K+ as
of August. Asking $295K.
4092 SAN JOSE GP
Well-established practice offering over 40 years of
goodwill. Fabulous location conveniently situated at two major
cross streets, right
ght offff Hwyy 280.
28 4 fully equipped ops in 1,400
sq. ft.Practice average
gross
ge
eg
ro
oss
sGs receipts $665K+ with average adj.
N
I
N+D 7 ddays of hygiene and 1,300-1,400
net income of $2
$223K+
2P23
2E
23K+
3K+
K
K+
active patients, alll fee-for-service
fee for servic (Delta Premier Provider only, no
other PPOs accepted). Seller is willing to help Buyer for a
smooth transition. This opportunity wont last long. Asking
$550K.
4088 NEWARK/FREMONT DENTAL FACILITY
1,400 sq. ft. facility with 4 fully-equipped operatories setup for
right-handed delivery, reception area, private office, consult room,
staff lounge, lab area, sterilization area, storage area, 2
bathrooms, common area and plenty of parking. Located in mall
close to new housing. Lease expires in 3 years with 5 year
option to renew. Landlord willing to negotiate new 10 year lease
at a fair market rate. Equipment list available. Asking $80K.
SF DENTAL FACILITY
Facility only in the Sunset district, located on Ocean Avenue. 2
fully equipped ops with room for a 3rd op. Asking price $85K.
Lease is transferable to Buyer.
Carroll & Company
2055 Woodside Road, Ste 160
Redwood City, CA 94061
P (650) 362-7004
F (650) 362-7007
dental@carrollandco.info
www.carrollandco.info
CA DRE #00777682
Mike Carroll
Pamela Carroll-Gardiner
F E B . 2 016 R E G U L ATO RY C O M P L I A N C E
C D A J O U R N A L , V O L 4 4 , N 2
Free eDelivery.
138F E B R U A R Y 2 01 6
Periscope
C D A J O U R N A L , V O L 4 4 , N 2
PERIODONTICS
DENTAL MATERIALS
Slot DE, Jorritsma KH, Cobb CM, Van der Weijden FA. The eect
of the thermal diode laser (wavelength 808-980 nm) in nonsurgical periodontal therapy: A systematic review and meta-analysis. J
Clin Periodontol 2014 Jul;41(7):681-92.
F E B R U A R Y 2 0 1 6 139
Largest
Broker in
Northern
California
Extensive Buyer
Database &
Unsurpassed
Exposure allows
us to offer you
BAY AREA
800.641.4179
NORTHERN CALIFORNIA
EN-340 SACRAMENTO: Large HMO practice!
3,400 sf w/ 10 ops and Plumbed for 1 addl
$950k
EN-378 LINCOLN: quality practice with a wonderful patient base! 1,369 sf w/ 2 op + 3 addl.
$170k
EN-379 ROSEVILLE: An amazing opportunity in
the location of your dreams! 1,040 sf w/ 3ops.
$295k
EN-464 ROCKLIN Facility: Dont miss out on
this remarkable opportunity! 2,150 sf w/ 4
ops. $150k
EN-475 ROSEVILLE Facility: Hesitate and you
might miss out on this opportunity! 875 sf
w/ 2 ops + 2 addl. $49.5k
EG-479 FOLSOM: History is alive here with
tributes to the past! 1,600 sf w/ 3ops.. $225k
EG-496 AUBURN: Associate-Driven HMO practice in Downtown. 3 fully equipped ops $315k
WPS@SUCCEED.NET
Edmond P. Cahill, JD
Tech Trends
C D A J O U R N A L , V O L 4 4 , N 2
Articial Intelligence
Hue (Phillips, Hue white E26 starter kit, $79.95; Hue white
142F E B R U A R Y 2 01 6
Thurs.Sat.
May 1214,
2016
Anaheim
Convention
Center
Register today
cdapresents.com
The Art
and Science
of Dentistry
Before wearing
UltraFit tray in
the mouth
800.552.5512 | ultradent.com
2016 Ultradent Products, Inc. All Rights Reserved.